CoChat

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma

Ohnstad, Hege O., Castro, Russell, Sun, Jinchang, Heintz, Karen‐Marie, Vassilev, Lyubomir T., Bjerkehagen, Bodil, Kresse, Stine H., Meza‐Zepeda, Leonardo A., Myklebost, Ola · 2013 · Cancer
Cited by 42

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Relatively few sarcomas harbor TP53 (tumor protein p53) mutations, but in many cases, amplification of MDM2 (murine double minute 2) effectively inactivate p53. The p53 pathway activity can also be affected by normal genetic variation. METHODS: The mutation status of TP53 and expression of MDM2, TP53, and their genetic variants SNP309 and R72P (Arg72Pro) were investigated in 125 sarcoma patient samples and 18 sarcoma cell lines. Association of the different genotypes and gene aberrations with chemotherapy response and survival, as well as response to MDM2 antagonists in vitro was evaluated. RESULTS: Twenty‐two percent of the tumors had mutant TP53 and 20% MDM2 gene amplification. Patients with wild‐type TP53 (TP53Wt) tumors had improved survival (P < .001) and TP53Wt was an independent prognostic factor (hazard ratio = 0.41; 95% confidence interval = 0.23‐0.74; P = .03). Interestingly, there was a trend toward longer time to progression after chemotherapy for tumors with the apoptosis‐prone p53 variant R72 (P = .07), which was strongest with doxorubicin/ifosfamide‐based regimens (P = .01). Liposarcomas had low R72 frequency (33% versus 56%), but increased levels of MDM2 and MDM4 (51% and 11%, P < .001). MDM2 overexpression on a TP53Wt background predicted better response to MDM2 antagonist Nutlin‐3a, irrespective of R72P or SNP309 status. CONCLUSIONS: Improved survival after chemotherapy was found in patients with TP53Wt tumors harboring the R72 variant. MDM2 overexpression in TP53Wt tumors predicted good response to MDM2 antagonists, irrespective of R72P or SNP309 status. Thus, detailed TP53 and MDM2 genotype analyses prior to systemic therapy are recommended. Cancer 2013. © 2012 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.27837

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. 10.1016/j.cellbi.2006.11.012 · DOI · Paper page
  2. Andreassen A, 1993, p53 abnormalities in different subtypes of human sarcomas, Cancer Res., 53, 468
  3. 10.1007/s000180050273 · DOI · Paper page
  4. 10.1093/jnci/86.17.1297 · DOI · Paper page
  5. 10.1038/sj.onc.1206671 · DOI
  6. Li FP, 1988, A cancer family syndrome in twenty‐four kindreds, Cancer Res., 48, 5358
  7. 10.1038/nrc2584 · DOI · Paper page
  8. 10.1002/ijc.23454 · DOI
  9. 10.1158/0008-5472.CAN-05-0825 · DOI · Paper page
  10. 10.1158/1055-9965.EPI-07-0634 · DOI
  11. 10.1159/000154228 · DOI · Paper page
  12. 10.1038/ng1093 · DOI · Paper page
  13. 10.1128/MCB.19.2.1092 · DOI · Paper page
  14. 10.1038/sj.onc.1207428 · DOI · Paper page
  15. 10.1038/sj.onc.1210199 · DOI · Paper page
  16. 10.1182/blood-2008-05-158634 · DOI
  17. 10.1002/ijc.23541 · DOI
  18. 10.1016/j.ccr.2010.12.019 · DOI
  19. Fletcher CDM, 2002, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone
  20. 10.1002/gcc.20717 · DOI · Paper page
  21. 10.1002/ijc.22643 · DOI · Paper page
  22. 10.1186/1471-2407-11-211 · DOI · Paper page
  23. 10.1073/pnas.96.13.7382 · DOI · Paper page
  24. Onat OE, 2006, MDM2 T309G polymorphism is associated with bladder cancer, Anticancer Res., 26, 3473
  25. Toguchida J, 1992, Mutation spectrum of the p53 gene in bone and soft tissue sarcomas, Cancer Res., 52, 6194
  26. 10.1002/ijc.23380 · DOI · Paper page
  27. 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2 · doi:10.1002/(sici)1098-2264(199612)17:4<254::aid-gcc7>3.0.co;2-2
  28. 10.1038/sj.onc.1201135 · DOI
  29. 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P · DOI · Paper page
  30. 10.1016/j.cancergencyto.2004.08.005 · DOI · Paper page
  31. 10.1158/1078-0432.CCR-08-2249 · DOI
  32. 10.1097/CCO.0b013e3283412dfa · DOI · Paper page
  33. 10.1158/1541-7786.1.2.1 · DOI · Paper page
  34. 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A · DOI · Paper page
  35. 10.1038/75586 · DOI · Paper page
  36. 10.4161/cc.9.7.11255 · DOI · Paper page

Cited by

See all 42

Metadata

Authors
Ohnstad, H. O., Castro, R., Sun, J., Heintz, K., Vassilev, L. T., Bjerkehagen, B., Kresse, S. H., Meza‐Zepeda, L. A., & Myklebost, O.
Venue
Cancer
Publisher
Wiley
Published
2012-11-16
Volume
119
Issue
5
Pages
1013-1022
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2071028149
Cited by
42
References
7
FWCI
2.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.